September 9, 2020 -- MilliporeSigma is expanding its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) manufacturing capabilities with a $65 million investment at its Madison, WI, facility.
The investment will support large-scale manufacturing of compounds that have the potential to treat cancer. The expansion is expected to be complete by mid-2022 and will add approximately 50 full-time jobs starting in 2021.
MilliporeSigma is expanding its ADC manufacturing capabilities. ADCs are an emerging class of medicines designed for high-specificity targeting and destruction of cancer cells, while preserving healthy ones. Image courtesy of MilliporeSigma.
The new 70,000-sq-ft commercial building will be a dedicated HPAPI manufacturing space designed to handle single-digit nanogram occupation exposure limit materials. The facility will incorporate containment areas to produce next-generation linker and payload materials for ADCs. The facility will add to the company's existing ADC manufacturing capabilities in St. Louis, MO.
Copyright © 2020 scienceboard.net